22S1 Stock Chart & Stats
$4.46
--
Market closed
$4.46
--
Day’s Range― - ―
52-Week Range$4.46 - $5.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
€598.14K
Enterprise Value$0.37
Total Cash (Recent Filing)€2.08M
Total Debt (Recent Filing)€265.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Aug 13, 2026EPS Estimate
-20.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2240.70
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)4.58
Price to Sales (P/S)1.45
P/FCF Ratio-1.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-70.35
Revenue Forecast (FY)€8.66M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 70% indicate the Aquadex product and consumable economics can generate healthy unit-level contribution. Durable gross profitability reduces revenue required to reach operating break-even and provides structural leverage as installed base and utilization grow, assuming SG&A is controlled.
Pediatric Commercial TractionStrong adoption in pediatrics creates a sticky installed base and recurring consumable demand. Placement in leading children's hospitals enhances clinical credibility and referral-driven growth, supporting durable procedure volumes and recurring revenue streams as hospitals standardize on Aquadex therapy.
Strategic Product Expansion And IPAcquiring RendiaTech and securing patent protection broadens the cardiorenal platform with bedside kidney monitoring and pediatric safety features. This structural expansion can increase clinical value, differentiation, cross-sell potential, and barriers to entry once the new product is commercialized.
Bears Say
Large Cash BurnMulti-year negative operating and free cash flow is a material structural weakness. Persistent cash burn forces reliance on external funding or aggressive cost cuts, constraining strategic investments and increasing execution risk if management cannot deliver the targeted burn reduction while sustaining commercial growth.
Eroded Equity BaseMaterial decline in shareholders' equity reflects cumulative losses and reduces the balance-sheet buffer. A thin equity base increases likelihood of dilution or restrictive financing terms to fund operations, weakening financial flexibility and the company's ability to withstand setbacks during commercialization scaling.
Modest Absolute Revenue ScaleAlthough growth rates are healthy, the current revenue base is small relative to operating expenses. This structural scale gap means percentage growth may not translate to profitability quickly; durable profitability will require sustained console placements, higher utilization, and recurring circuit sales over multiple quarters.
Nuwellis News
22S1 FAQ
What was Nuwellis, Inc.’s price range in the past 12 months?
Nuwellis, Inc. lowest stock price was $4.46 and its highest was $5.19 in the past 12 months.
What is Nuwellis, Inc.’s market cap?
Nuwellis, Inc.’s market cap is €598.14K.
When is Nuwellis, Inc.’s upcoming earnings report date?
Nuwellis, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 13 days.
How were Nuwellis, Inc.’s earnings last quarter?
Nuwellis, Inc. released its earnings results on May 12, 2026. The company reported -$63.548 earnings per share for the quarter, missing the consensus estimate of -$30.406 by -$33.142.
Is Nuwellis, Inc. overvalued?
According to Wall Street analysts Nuwellis, Inc.’s price is currently Overvalued.
Does Nuwellis, Inc. pay dividends?
Nuwellis, Inc. does not currently pay dividends.
What is Nuwellis, Inc.’s EPS estimate?
Nuwellis, Inc.’s EPS estimate is -20.68.
How many shares outstanding does Nuwellis, Inc. have?
Currently, no data Available
What happened to Nuwellis, Inc.’s price movement after its last earnings report?
Nuwellis, Inc. reported an EPS of -$63.548 in its last earnings report, missing expectations of -$30.406. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nuwellis, Inc.?
Currently, no hedge funds are holding shares in DE:22S1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuwellis, Inc.
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
22S1 Earnings Call
Q1 2026
0:00 / 0:00
22S1 Stock 12 Month Forecast
Average Price Target
―Aethlon Medical
―
PAVmed
―
Catheter Precision
―
Bone Biologics
―
Heart Test Laboratories, Inc.
―